Close Menu

Becton Dickinson

Among the updates provided Wednesday, Quidel's CEO noted the firm's growing presence in point-of-care markets, while PerkinElmer discussed plans for its Vanadis test.


The enteric panel detects the viral cause of infectious diarrhea symptoms including norovirus, rotavirus, adenovirus, human astrovirus, and sapovirus.

The company developed the test with Boston University researchers as part of an effort to push its surface-enhanced Raman scattering tech for POC applications.

The FDA cleared BD's test for detecting carbapenemase-producing organisms, which can be used by hospitals to contain the spread of antimicrobial resistance.

The firm's full fiscal year revenues were also up, 32 percent as reported, or about 6 percent on a currency-neutral basis.

Quest Diagnostics this week announced it is acquiring the outreach laboratory services of Marin General Hospital located in Greenbrae, California.

The investment bank expects Abbott's Diagnostic division to grow in the mid-single digits driven in part by global launches of its Alinity systems.

The PCR assay is intended to help detect TB-causing bacteria and determine if it harbors mutations associated with isoniazid and rifampicin resistance.

Becton Dickinson got clearance for a platform and test for the rapid identification and determination of antimicrobial susceptibility of gram-negative bacteria.

The firm said that its system is expected to deliver up to 50 AST tests per day and match the daily production of the highest-throughput systems in the market.

Pages